WO2025219948A1 - Formes cristallines de govorestat - Google Patents

Formes cristallines de govorestat

Info

Publication number
WO2025219948A1
WO2025219948A1 PCT/IB2025/054075 IB2025054075W WO2025219948A1 WO 2025219948 A1 WO2025219948 A1 WO 2025219948A1 IB 2025054075 W IB2025054075 W IB 2025054075W WO 2025219948 A1 WO2025219948 A1 WO 2025219948A1
Authority
WO
WIPO (PCT)
Prior art keywords
govorestat
crystalline
theta
degrees
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2025/054075
Other languages
English (en)
Inventor
Anantha Rajmohan MUTHUSAMY
Amit Singh
Drishti Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assia Chemical Industries Ltd
Original Assignee
Assia Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assia Chemical Industries Ltd filed Critical Assia Chemical Industries Ltd
Publication of WO2025219948A1 publication Critical patent/WO2025219948A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Definitions

  • the present disclosure encompasses solid state forms of Govorestat, in embodiments crystalline polymorphs of Govorestat, processes for preparation thereof, and pharmaceutical compositions thereof.
  • Govorestat is an investigational Aldose Reductase Inhibitor (ARI) being developed for the treatment of several rare diseases; including: Galactosemia, and sorbitol dehydrogenase deficiency.
  • ARI Aldose Reductase Inhibitor
  • Govorestat is also under investigation for the treatment of Phosphomannomutase 2 Deficiency, a congenital disorder of glycosylation (PMM2-CDG). The compound is described in International Publication No. WO2017/223179.
  • Polymorphism the occurrence of different crystalline forms, is a property of some molecules and molecular complexes.
  • a single molecule may give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviors (e.g., measured by thermogravimetric analysis (“TGA”), or differential scanning calorimetry (“DSC”)), X-ray diffraction (XRD) pattern, infrared absorption fingerprint, and solid state ( 13 C) NMR spectrum.
  • TGA thermogravimetric analysis
  • DSC differential scanning calorimetry
  • XRD X-ray diffraction
  • 13 C solid state
  • Such variations in the properties of different salts and solid state forms and solvates may provide a basis for improving formulation, for example, by facilitating better processing or handling characteristics, changing the dissolution profile in a favorable direction, or improving stability (polymorph as well as chemical stability) and shelf-life. These variations in the properties of different salts and solid state forms may also offer improvements to the final dosage form, for instance, if they serve to improve bioavailability. Different salts and solid state forms and solvates of an active pharmaceutical ingredient may also give rise to a variety of polymorphs or crystalline forms, which may in turn provide additional opportunities to assess variations in the properties and characteristics of a solid active pharmaceutical ingredient.
  • New solid state forms and solvates of a pharmaceutical product may yield materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms.
  • New solid state forms of a pharmaceutically useful compound can also provide an opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for formulation optimization, for example by providing a product with different properties, including a different crystal habit, higher crystallinity, or polymorphic stability, which may offer better processing or handling characteristics, improved dissolution profile, or improved shelf-life (chemi cal/phy si cal stability). For at least these reasons, there is a need for additional solid state forms (including solvated forms) of Govorestat.
  • the present disclosure provides crystalline polymorphs of Govorestat, in embodiments crystalline polymorphs of Govorestat, processes for preparation thereof, and pharmaceutical compositions thereof.
  • the present disclosure also provides uses of said solid state forms of Govorestat in the preparation of other solid state forms of Govorestat or salts and/or co-crystals thereof.
  • the present disclosure provides said crystalline forms of Govorestat for use in medicine, including for the treatment of Galactosemia, and sorbitol dehydrogenase deficiency.
  • the present disclosure provides crystalline forms of Govorestat for treating multiple rare diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency and Phosphomannomutase 2 Deficiency.
  • SORD Sorbitol Dehydrogenase
  • the present disclosure also encompasses the use of said crystalline polymorphs of Govorestat for the preparation of pharmaceutical compositions and/or formulations.
  • the present disclosure provides pharmaceutical compositions comprising said crystalline Govorestat according to the present disclosure.
  • the present disclosure includes processes for preparing the above mentioned pharmaceutical compositions.
  • the processes include combining said crystalline polymorphs of Govorestat with at least one pharmaceutically acceptable excipient.
  • the crystalline polymorphs of Govorestat as defined herein and the pharmaceutical compositions or formulations of the crystalline polymorphs of Govorestat may be used as medicaments, such as for the treatment of Galactosemia, and sorbitol dehydrogenase deficiency.
  • the present disclosure also provides methods for the treatment of patients with Galactosemia or sorbitol dehydrogenase deficiency by administering a therapeutically effective amount of said crystalline polymorph of Govorestat of the present disclosure, or at least one of the above pharmaceutical compositions, to a subject suffering from Galactosemia or sorbitol dehydrogenase deficiency or otherwise in need of the treatment.
  • the present disclosure also provides uses of crystalline polymorphs of Govorestat of the present disclosure or at least one of the above pharmaceutical compositions, for the manufacture of medicaments for treating e.g., Galactosemia, and sorbitol dehydrogenase deficiency.
  • FIG. 1 shows a characteristic X-ray powder diffraction pattern (XRPD) of Govorestat Form G1.
  • FIG. 2 shows a characteristic X-ray powder diffraction pattern (XRPD) of Govorestat Form G2.
  • FIG. 3 shows a characteristic X-ray powder diffraction pattern (XRPD) of Govorestat Form G3.
  • FIG. 4 shows a characteristic X-ray powder diffraction pattern (XRPD) of Govorestat Form G4.
  • FIG. 5 shows a characteristic X-ray powder diffraction pattern (XRPD) of Govorestat Form G5.
  • FIG. 6 shows a characteristic solid state 13 C NMR spectrum of Govorestat- Form G1 (full screen).
  • FIG. 7 shows solid state 13 C NMR spectrum of Govorestat- Form G1 (0-100 ppm).
  • FIG. 8 shows solid state 13 C NMR spectrum of Govorestat- Form G1 (100-
  • FIG. 9 shows a characteristic solid state 13 C NMR spectrum of Govorestat- Form G2 (full screen).
  • FIG. 10 shows solid state 13 C NMR spectrum of Govorestat- Form G2 (0-100 ppm).
  • FIG. 11 shows solid state 13 C NMR spectrum of Govorestat- Form G2 (100-
  • the present disclosure encompasses solid state forms of Govorestat, in embodiments crystalline polymorphs of Govorestat, processes for preparation thereof, and pharmaceutical compositions thereof.
  • Solid state properties of Govorestat and crystalline polymorphs thereof can be influenced by controlling the conditions under which Govorestat and crystalline polymorphs thereof are obtained in solid form.
  • the solid state forms of Govorestat as described in any aspect or embodiment of the present disclosure may be polymorphically pure, or substantially free of any other solid state (or polymorphic) forms.
  • a solid state form may be referred to herein as polymorphically pure or as substantially free of any other solid state (or polymorphic) forms.
  • the expression “substantially free of any other forms” will be understood to mean that the solid state form contains about 20% (w/w) or less, about 10% (w/w) or less, about 5% (w/w) or less, about 2% (w/w) or less, about 1% (w/w) or less, or about 0% of any other forms of the subject compound as measured, for example, by XRPD.
  • polymorphically pure Govorestat means that the solid state form is substantially free of other solid state forms of Govorestat.
  • a crystalline polymorph of Govorestat described herein as substantially free of any other solid state forms would be understood to contain greater than about 80% (w/w), greater than about 90% (w/w), greater than about 95% (w/w), greater than about 98% (w/w), greater than about 99% (w/w), or about 100% of the subject crystalline polymorph of Govorestat.
  • the described crystalline polymorph of Govorestat, salt or cocrystal may contain from about 1% to about 20% (w/w), from about 5% to about 20% (w/w), or from about 5% to about 10% (w/w) of one or more other crystalline polymorph of the same Govorestat.
  • the crystalline polymorphs of Govorestat of the present disclosure may have advantageous properties selected from at least one of the following: chemical purity, flowability, solubility, dissolution rate, morphology or crystal habit, stability, such as chemical stability as well as thermal and mechanical stability with respect to polymorphic conversion, stability towards dehydration and/or storage stability, low content of residual solvent, a lower degree of hygroscopicity, flowability, and advantageous processing and handling characteristics such as compressibility and bulk density.
  • a solid state form such as a crystal form or an amorphous form, may be referred to herein as being characterized by graphical data “as depicted in” or “as substantially depicted in” a figure
  • graphical data include, for example, powder X-ray diffractograms and solid state NMR spectra.
  • the graphical data potentially provides additional technical information to further define the respective solid state form (a so-called “fingerprint”) which cannot necessarily be described by reference to numerical values or peak positions alone.
  • the term "isolated" in reference to crystalline polymorph of Govorestat of the present disclosure corresponds to a crystalline polymorph of Govorestat that is physically separated from the reaction mixture in which it is formed.
  • the 13 C scale is referenced to a-glycine.
  • a thing e.g., a reaction mixture
  • room temperature or “ambient temperature,” often abbreviated as “RT ”
  • RT room temperature
  • room temperature is from about 20°C to about 30°C, or about 22°C to about 27°C, or about 25°C.
  • the amount of solvent employed in a chemical process may be referred to herein as a number of “volumes” or “vol” or “V.”
  • a material may be referred to as being suspended in 10 volumes (or 10 vol or 10V) of a solvent.
  • this expression would be understood to mean milliliters of the solvent per gram of the material being suspended, such that suspending a 5 grams of a material in 10 volumes of a solvent means that the solvent is used in an amount of 10 milliliters of the solvent per gram of the material that is being suspended or, in this example, 50 mL of the solvent.
  • v/v may be used to indicate the number of volumes of a solvent that are added to a liquid mixture based on the volume of that mixture. For example, adding solvent X (1.5 v/v) to a 100 ml reaction mixture would indicate that 150 mL of solvent X was added.
  • a process or step may be referred to herein as being carried out “overnight.” This refers to a time interval, e.g., for the process or step, that spans the time during the night, when that process or step may not be actively observed. This time interval is from about 8 to about 20 hours, or about 10-18 hours, in some cases about 16 hours.
  • reduced pressure refers to a pressure that is less than atmospheric pressure.
  • reduced pressure is about 10 mbar to about 50 mbar.
  • ambient conditions refer to atmospheric pressure and a temperature of 22-24°C.
  • the solid state forms of Govorestat as described in any aspect or embodiment of the present disclosure may be chemically pure, or substantially free of any other compounds.
  • a compound may be referred to herein as chemically pure or purified compound or as substantially free of any other compounds.
  • the terms "chemically pure” or “purified” or “substantially free of any other compounds” refer to a compound that is substantially free of any impurities including enantiomers of the subject compound, or other isomers.
  • a chemically pure or purified compound or a compound that is substantially free of any other compound will be understood to mean that it contains about 10% (w/w) or less, about 5% (w/w) or less, about 4% (w/w) or less, about 3% (w/w) or less, about 2% (w/w) or less, about 1.5% (w/w) or less, about 1% (w/w) or less, about 0.8% (w/w) or less, about 0.6% (w/w) or less, about 0.4% (w/w) or less, about 0.2% (w/w) or less, about 0.1% (w/w) or less, or about 0% of any other compound as measured, for example, by HPLC.
  • a chemically pure or purified compound or a compound that is substantially free of any other compound will be understood to mean that it contains about 10% area percent or less, about 5% area percent or less, about 4% area percent or less, about 3% area percent or less, about 2% area percent or less, about 1.5% area percent or less, about 1% area percent or less, about 0.8% area percent or less, about 0.6% area percent or less, about 0.4% area percent or less, about 0.2% area percent or less, about 0.1% area percent or less, or about 0% of any other compound as measured by HPLC.
  • pure or purified Govorestat described herein as substantially free of any compounds would be understood to contain greater than about 90% area percent, greater than about 95% area percent, greater than about 96% area percent, greater than about 97% area percent, greater than about 98% area percent, greater than about 98.5% area percent, greater than about 99% area percent, greater than about 99.2% area percent, greater than about 99.4% area percent, greater than about 99.6% area percent, greater than about 99.8% area percent, greater than about 99.9% area percent, or about 100% of the subject Govorestat.
  • the present disclosure includes crystalline Govorestat.
  • crystalline Govorestat may be anhydrous.
  • the present disclosure relates to crystalline Govorestat which is anhydrous.
  • the crystalline Govorestat may be polymorphically pure.
  • the crystalline Govorestat may contain: about 20% (w/w) or less, about 10% (w/w) or less, about 5% (w/w) or less, about 2% (w/w) or less, about 1% (w/w) or less, or about 0% of amorphous Govorestat, for example, as measured by XRPD.
  • the present disclosure includes a crystalline polymorph of Govorestat designated Form Gl.
  • the crystalline Form G1 of Govorestat may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in FIG. 1; an X-ray powder diffraction pattern having peaks at 17.8, 19.5, 23.3, 28.0 and 29.6 degrees 2-theta ⁇ 0.2 degrees 2-theta; and combinations of these data.
  • Crystalline Form Gl of Govorestat may be further characterized by an X-ray powder diffraction pattern having peaks at 17.8, 19.5, 23.3, 28.0 and 29.6 degrees 2-theta ⁇ 0.2 degrees 2-theta, and also having one, two, three, or four additional peaks selected from 6.6, 13.8, 20.2 and 24.8 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • Crystalline Form Gl of Govorestat may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 6.6, 13.8, 17.8, 19.5, 20.2, 23.3, 24.8, 28.0 and 29.6 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • Crystalline Form Gl of Govorestat may be additionally characterized by an XRPD pattern having an absence of peaks at any one or more of: 7.2 to 11 degrees 2-theta ⁇ 0.2 degrees 2-theta; and/or 14.9 to 15.1 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • crystalline Form Gl of Govorestat may be additionally characterized by an XRPD pattern having an absence of peaks at any one or more of: 2.8 to 6.2 degrees 2-theta ⁇ 0.2 degrees 2-theta, 7.2 to 11.0 degrees 2-theta ⁇ 0.2 degrees 2- theta; and/or 14.9 to 15.1 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • Crystalline Form Gl of Govorestat as described in any aspect or embodiment of the disclosure may be alternatively or additionally characterized by a solid state 13 C NMR spectrum with peaks at 39.9, 54.9, 118.9, 134.6, 158.5 and 167.2 ppm ⁇ 0.2 ppm.
  • crystalline Form Gl of Govorestat may be characterized by a solid state 13 C NMR spectrum having the following chemical shift absolute differences from a peak at 140.2 ppm ⁇ 2 ppm of 100.3, 85.3, 21.3, 5.6, 18.3 and 27.0 ppm ⁇ 0.1 ppm; optionally, Form Gl of Govorestat may be characterized by a solid state 13 C NMR spectrum substantially as depicted in any of Figures 6, 7 or 8, preferably Figure 6.
  • crystalline Form Gl of Govorestat may be isolated.
  • crystalline Form G1 of Govorestat may be anhydrous.
  • crystalline Form G1 of Govorestat may be polymorphically pure.
  • the present disclosure includes a crystalline polymorph of Govorestat designated Form G2.
  • the crystalline Form G2 of Govorestat may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in FIG. 2; an X-ray powder diffraction pattern having peaks at 6.2, 7.1, 12.4, 14.2 and 18.7 degrees 2-theta ⁇ 0.2 degrees 2-theta; and combinations of these data.
  • Crystalline Form G2 of Govorestat may be further characterized by an X-ray powder diffraction pattern having peaks at 6.2, 7.1, 12.4, 14.2 and 18.7 degrees 2-theta ⁇ 0.2 degrees 2-theta, and also having one, two, three, or four additional peaks selected from 10.4, 26.7, 29.3 and 30.4 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • Crystalline Form G2 of Govorestat may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 6.2, 7.1, 10.4, 12.4, 14.2, 18.7, 26.7, 29.3 and 30.4 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • Crystalline Form G2 of Govorestat may be additionally characterized by an XRPD pattern having an absence of peaks at any one or more of: 8.8 to 9.9 degrees 2-theta ⁇ 0.2 degrees 2-theta; 13.4 to 13.7 degrees 2-theta ⁇ 0.2 degrees 2-theta; and/or 17.2 to 17.6 degrees 2-theta ⁇ 0.2 degrees 2-theta
  • Crystalline Form G2 of Govorestat as described in any aspect or embodiment of the disclosure may be alternatively or additionally characterized by a solid state 13 C NMR spectrum with peaks at 36.2, 49.7, 124.7, 132.7, 149.8 and 155.9 ppm ⁇ 0.2 ppm.
  • crystalline Form G2 of Govorestat may be characterized by a solid state 13 C NMR spectrum having the following chemical shift absolute differences from a peak at 140.2 ppm ⁇ 2 ppm of 104.0, 90.5, 15.5, 7.5, 9.6 and 15.7 ppm ⁇ 0.1 ppm; optionally, Form G2 of Govorestat may be characterized by a solid state 13 C NMR spectrum substantially as depicted in any of Figures 9, 10 or 11, preferably Figure 9.
  • crystalline Form G2 of Govorestat may be isolated.
  • crystalline Form G2 of Govorestat may be anhydrous.
  • crystalline Form G2 of Govorestat may be polymorphically pure.
  • Crystalline Form G2 of Govorestat is stable under all tested stress conditions (e.g., under strong grinding, pressure of 2 tons, high humidity (up to 100% RH for 7 days) and at high temperature (up to 100°C).
  • the present disclosure includes a crystalline polymorph of Govorestat designated Form G3.
  • the crystalline Form G3 of Govorestat may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in FIG. 3; an X-ray powder diffraction pattern having peaks at 9.8, 16.0, 18.9, 21.3 and 24.0 degrees 2-theta ⁇ 0.2 degrees 2-theta; and combinations of these data.
  • Crystalline Form G3 of Govorestat may be further characterized by an X-ray powder diffraction pattern having peaks at 9.8, 16.0, 18.9, 21.3 and 24.0 degrees 2-theta ⁇ 0.2 degrees 2-theta, and also having one, two, or three additional peaks selected from 14.0, 19.6 and 31.8 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • Crystalline Form G3 of Govorestat may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 9.8, 14.0, 16.0, 18.9, 19.6, 21.3, 24.0 and 31.8 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • crystalline Form G3 of Govorestat may be isolated.
  • crystalline Form G3 of Govorestat may be a solvate; in particular, N,N-Dimethylacetamide solvate.
  • crystalline Form G3 of Govorestat may be polymorphically pure.
  • the present disclosure provides a crystalline polymorph of Govorestat designated Form G4.
  • the crystalline Form G4 of Govorestat may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in FIG. 4; an X-ray powder diffraction pattern having peaks at 6.2, 12.0, 16.9, 24.2 and 26.7 degrees 2-theta ⁇ 0.2 degrees 2-theta; and combinations of these data.
  • Crystalline Form G4 of Govorestat may be further characterized by an X-ray powder diffraction pattern having peaks at 6.2, 12.0, 16.9, 24.2 and 26.7 degrees 2-theta ⁇ 0.2 degrees 2-theta, and also having one, two, three, or four additional peaks selected from 4.4, 16.0, 18.4 and 20.4 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • Crystalline Form G4 of Govorestat may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 4.4, 6.2, 12.0, 16.0, 16.9, 18.4, 20.4, 24.2 and 26.7 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • crystalline Form G4 of Govorestat may be isolated.
  • crystalline Form G4 of Govorestat may be a solvate; in particular, aniline solvate.
  • crystalline Form G4 of Govorestat may be polymorphically pure.
  • the present disclosure includes a crystalline polymorph of Govorestat designated Form G5.
  • the crystalline Form G5 of Govorestat may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in FIG. 5; an X-ray powder diffraction pattern having peaks at 4.6, 8.6, 12.1, 13.3 and 17.2 degrees 2-theta ⁇ 0.2 degrees 2-theta; and combinations of these data.
  • Crystalline Form G5 of Govorestat may be further characterized by an X-ray powder diffraction pattern having peaks at 4.6, 8.6, 12.1, 13.3 and 17.2 degrees 2-theta ⁇ 0.2 degrees 2-theta, and also having one, two, three, or four additional peaks selected from 6.4, 16.0, 17.7 and 20.3 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • Crystalline Form G5 of Govorestat may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 4.6, 6.4, 8.6, 12.1, 13.3, 16.0, 17.2, 17.7 and 20.3 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • crystalline Form G5 of Govorestat may be isolated.
  • crystalline Form G5 of Govorestat may be polymorphically pure.
  • the present disclosure provides the above described crystalline polymorph of Govorestat for use in the preparation of pharmaceutical compositions comprising Govorestat and/or solid state forms thereof.
  • the present disclosure also encompasses the use of crystalline polymorph of Govorestat of the present disclosure for the preparation of pharmaceutical compositions of the crystalline polymorph Govorestat.
  • the present disclosure includes processes for preparing the above mentioned pharmaceutical compositions.
  • the processes include combining any one or a combination of the crystalline polymorphs of Govorestat of the present disclosure with at least one pharmaceutically acceptable excipient.
  • compositions of the present disclosure contain any one or a combination of the solid state form of Govorestat of the present disclosure.
  • the pharmaceutical formulations of the present disclosure can contain one or more excipients. Excipients are added to the formulation for a variety of purposes.
  • Diluents increase the bulk of a solid pharmaceutical composition, and can make a pharmaceutical dosage form containing the composition easier for the patient and caregiver to handle.
  • Diluents for solid compositions include, for example, microcrystalline cellulose (e.g., Avicel®), microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g., Eudragit®), potassium chloride, powdered cellulose, sodium chloride, sorbitol, and talc.
  • microcrystalline cellulose e.g., Avicel®
  • microfine cellulose lactose
  • starch pregelatinized starch
  • calcium carbonate calcium sulfate
  • sugar dextrates
  • Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet can include excipients whose functions include helping to bind the active ingredient and other excipients together after compression.
  • Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel®), hydroxypropyl methyl cellulose (e.g.
  • Methocel® liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Kollidon®, Plasdone®), pregelatinized starch, sodium alginate, and starch.
  • povidone e.g. Kollidon®, Plasdone®
  • pregelatinized starch sodium alginate, and starch.
  • the dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach can be increased by the addition of a disintegrant to the composition.
  • Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g., Ac-Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g., Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g., Explotab®), and starch.
  • alginic acid include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g., Ac-Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g., Kollidon®, Poly
  • Glidants can be added to improve the flowability of a non-compacted solid composition and to improve the accuracy of dosing.
  • Excipients that can function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, and tribasic calcium phosphate.
  • a dosage form such as a tablet is made by the compaction of a powdered composition, the composition is subjected to pressure from a punch and dye. Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and dye, which can cause the product to have pitting and other surface irregularities.
  • a lubricant can be added to the composition to reduce adhesion and ease the release of the product from the dye.
  • Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and zinc stearate.
  • Flavoring agents and flavor enhancers make the dosage form more palatable to the patient.
  • Common flavoring agents and flavor enhancers for pharmaceutical products that can be included in the composition of the present disclosure include maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid.
  • Solid and liquid compositions can also be dyed using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.
  • liquid pharmaceutical compositions of the present invention Govorestat and any other solid excipients can be dissolved or suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol, or glycerin.
  • a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol, or glycerin.
  • Liquid pharmaceutical compositions can contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier.
  • Emulsifying agents that can be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol, and cetyl alcohol.
  • Liquid pharmaceutical compositions of the present invention can also contain a viscosity enhancing agent to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract.
  • a viscosity enhancing agent include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth, xanthan gum and combinations thereof.
  • Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol, and invert sugar can be added to improve the taste.
  • Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxyl toluene, butylated hydroxyanisole, and ethylenediamine tetraacetic acid can be added at levels safe for ingestion to improve storage stability.
  • a liquid composition can also contain a buffer such as gluconic acid, lactic acid, citric acid, or acetic acid, sodium gluconate, sodium lactate, sodium citrate, or sodium acetate. Selection of excipients and the amounts used can be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
  • a buffer such as gluconic acid, lactic acid, citric acid, or acetic acid, sodium gluconate, sodium lactate, sodium citrate, or sodium acetate.
  • the solid compositions of the present disclosure include powders, granulates, aggregates, and compacted compositions.
  • the dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant, and ophthalmic administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, in embodiments the route of administration is oral.
  • the dosages can be conveniently presented in unit dosage form and prepared by any of the methods well-known in the pharmaceutical arts.
  • Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches, and lozenges, as well as liquid syrups, suspensions, and elixirs.
  • the dosage form of the present disclosure can be a capsule containing the composition, such as a powdered or granulated solid composition of the disclosure, within either a hard or soft shell.
  • the shell can be made from gelatin and optionally contain a plasticizer such as glycerin and/or sorbitol, an opacifying agent and/or colorant.
  • compositions and dosage forms can be formulated into compositions and dosage forms according to methods known in the art.
  • a composition for tableting or capsule filling can be prepared by wet granulation.
  • wet granulation some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water that causes the powders to clump into granules.
  • the granulate is screened and/or milled, dried, and then screened and/or milled to the desired particle size.
  • the granulate can then be tableted, or other excipients can be added prior to tableting, such as a glidant and/or a lubricant.
  • a tableting composition can be prepared conventionally by dry blending.
  • the blended composition of the actives and excipients can be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules can subsequently be compressed into a tablet.
  • a blended composition can be compressed directly into a compacted dosage form using direct compression techniques. Direct compression produces a more uniform tablet without granules.
  • Excipients that are particularly well suited for direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate, and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.
  • a capsule filling of the present disclosure can include any of the aforementioned blends and granulates that were described with reference to tableting, but they are not subjected to a final tableting step.
  • a pharmaceutical formulation of Govorestat can be administered.
  • Govorestat may be formulated for administration to a mammal, in embodiments to a human, by injection.
  • Govorestat can be formulated, for example, as a viscous liquid solution or suspension, such as a clear solution, for injection.
  • the formulation can contain one or more solvents.
  • a suitable solvent can be selected by considering the solvent's physical and chemical stability at various pH levels, viscosity (which would allow for syringeability), fluidity, boiling point, miscibility, and purity.
  • Suitable solvents include alcohol USP, benzyl alcohol NF, benzyl benzoate USP, and Castor oil USP. Additional substances can be added to the formulation such as buffers, solubilizers, and antioxidants, among others.
  • Ansel et al. Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed.
  • the crystalline polymorph of Govorestat and the pharmaceutical compositions and/or formulations of Govorestat of the present disclosure can be used as medicaments, in embodiments for the treatment of patients with Galactosemia, and sorbitol dehydrogenase deficiency
  • the present disclosure also provides methods of treating of patients with Galactosemia and sorbitol dehydrogenase deficiency, by administering a therapeutically effective amount of any one or a combination of the crystalline polymorphs of Govorestat of the present disclosure, or at least one of the above pharmaceutical compositions and/or formulations, to a subject in need of the treatment.
  • Scan range 2 - 40 degrees 2-theta
  • Step size 0.05 degrees
  • Sample holder PMMA specimen holder ring with silicon low background.
  • the 13 C CP/MAS NMR spectra employing cross-polarization were acquired using the standard cross-polarization pulse scheme at spinning frequency of 11 kHz.
  • the cross- polarization contact time was 2 ms, and the dipolar decoupling SPINAL64 was applied during the data acquisition.
  • the spectral width was 300 ppm with the resonance offset of 100 ppm.
  • the 13 C scale was referenced to a-glycine (176.03 ppm for 13 C).
  • the ’H scale was referenced to a-glycine (8.5 ppm for NHL signal).
  • Govorestat can be prepared according to methods known from the literature, for example according to the disclosure in International Publication No. WO2017/223179.
  • Form G3 of Govorestat (0.1g) was charged in a petridish and dried under vacuum oven at about 100°C for about 1 hour. The sample was cooled down to room temperature and analyzed by XRD- Form G2 of Govorestat was obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La demande concerne des polymorphes cristallins de Govorestat, leurs procédés de préparation et des compositions pharmaceutiques associées.
PCT/IB2025/054075 2024-04-17 2025-04-17 Formes cristallines de govorestat Pending WO2025219948A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN202411030891 2024-04-17
IN202411030891 2024-04-17
IN202411046807 2024-06-18
IN202411046807 2024-06-18

Publications (1)

Publication Number Publication Date
WO2025219948A1 true WO2025219948A1 (fr) 2025-10-23

Family

ID=95784135

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2025/054075 Pending WO2025219948A1 (fr) 2024-04-17 2025-04-17 Formes cristallines de govorestat

Country Status (1)

Country Link
WO (1) WO2025219948A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223179A1 (fr) 2016-06-21 2017-12-28 The Trustees Of Columbia University In The City Of New York Inhibiteurs d'aldose réductase et procédés d'utilisation associés
WO2019023648A1 (fr) * 2017-07-28 2019-01-31 Applied Therapeutics Inc. Compositions et méthodes de traitement de la galactosémie
WO2021222165A1 (fr) * 2020-05-01 2021-11-04 Applied Therapeutics, Inc. Inhibiteurs d'aldose réductase pour le traitement d'une déficience en sorbitol déshydrogénase
WO2024064147A1 (fr) * 2022-09-20 2024-03-28 Mayo Foundation For Medical Education And Research Traitement de troubles congénitaux de glycosylation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223179A1 (fr) 2016-06-21 2017-12-28 The Trustees Of Columbia University In The City Of New York Inhibiteurs d'aldose réductase et procédés d'utilisation associés
WO2019023648A1 (fr) * 2017-07-28 2019-01-31 Applied Therapeutics Inc. Compositions et méthodes de traitement de la galactosémie
WO2021222165A1 (fr) * 2020-05-01 2021-11-04 Applied Therapeutics, Inc. Inhibiteurs d'aldose réductase pour le traitement d'une déficience en sorbitol déshydrogénase
WO2024064147A1 (fr) * 2022-09-20 2024-03-28 Mayo Foundation For Medical Education And Research Traitement de troubles congénitaux de glycosylation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANSEL ET AL.: "Pharmaceutical Dosage Forms and Drug Delivery Systems"
BYRN, S. ET AL.: "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", PHARMACEUTICAL RESEARCH, vol. 12, no. 7, 1995, pages 945 - 954, XP055531015, Retrieved from the Internet <URL:https://link.springer.com/article/10.1023/A:1016241927429> DOI: 10.1023/A:1016241927429 *

Similar Documents

Publication Publication Date Title
US20240246949A1 (en) Solid state forms of lanifibranor and process for preparation thereof
WO2023064519A1 (fr) Formes à l&#39;état solide d&#39;élacestrant et leurs processus de préparation
EP4423085A1 (fr) Formes à l&#39;état solide de l&#39;ensifentrine et leur procédé de préparation
IL290185B1 (en) Crystalline forms of risperidone and the process for their preparation
WO2024121805A1 (fr) Formes à l&#39;état solide de zipalertinib et leur procédé de préparation
WO2024134498A1 (fr) Formes à l&#39;état solide d&#39;aficamten et leur procédé de préparation
EP4482836A1 (fr) Formes à l&#39;état solide de gusacitinib
WO2023096954A1 (fr) Formes à l&#39;état solide de sels de nirogacestat
US20230103724A1 (en) Solid state forms of avapritinib and process for preparation thereof
WO2021216628A1 (fr) Formes solides de trifarotène et leur procédé de préparation
WO2025219948A1 (fr) Formes cristallines de govorestat
US20250361221A1 (en) Solid state forms of paltusotine and process for preparation thereof
US20240246914A1 (en) Solid state form of centanafadine hcl and process for preparation thereof
WO2025210540A1 (fr) Formes à l&#39;état solide du camlipixant et leur procédé de préparation
WO2024069574A1 (fr) Formes à l&#39;état solide de denifanstat
WO2025257758A1 (fr) Formes à l&#39;état solide de navacaprant
WO2025017530A1 (fr) Formes solides de buntanetap et leur procédé de préparation
WO2026083289A1 (fr) Formes à l&#39;état solide d&#39;azénosertib
WO2025078973A1 (fr) Formes à l&#39;état solide de linerixibat et leur procédé de préparation
EP4608506A1 (fr) Formes à l&#39;état solide de sels de cilofexor
WO2026003808A1 (fr) Forme à l&#39;état solide d&#39;adagrasib et procédé de préparation
WO2026003809A1 (fr) Formes à l&#39;état solide de chlorhydrate d&#39;iptacopan
WO2025233905A1 (fr) Formes à l&#39;état solide de l&#39;upacicalcet et leur procédé de préparation
WO2024147096A1 (fr) Formes de brilaroxazine à l&#39;état solide et sels de brilaroxazine
WO2026018214A1 (fr) Formes à l&#39;état solide du tinlarebant et leur procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25726795

Country of ref document: EP

Kind code of ref document: A1